OrthoPediatrics Corp. filed its Form 10-Q with the U.S. Securities and Exchange Commission on August 5, 2026, covering the quarterly period ended June 30, 2026, and reporting continued net losses alongside revenue growth compared to the prior-year period.

Key Highlights

  • Net revenue of $70,508 thousand for the three months ended June 30, 2026, compared to $61,082 thousand for the same period in 2025, according to the filing.
  • Gross profit of $52,366 thousand for Q2 2026, up from $44,019 thousand in Q2 2025, as reported in the condensed consolidated statements of operations.
  • Operating loss of $4,068 thousand for the three months ended June 30, 2026, an improvement from an operating loss of $10,657 thousand in Q2 2025.
  • Net loss of $7,163 thousand for Q2 2026, compared to a net loss before income taxes of $7,064 thousand in Q2 2025, per the filing.
  • Total assets of $511,388 thousand as of June 30, 2026, versus $508,630 thousand as of December 31, 2025.
  • Accumulated deficit of $293,062 thousand as of June 30, 2026, compared to $275,212 thousand at December 31, 2025.
  • 26,109,788 shares of common stock outstanding as of August 4, 2026, as stated on the cover page of the filing.

OrthoPediatrics Q2 2026: Revenue Growth With Ongoing Operating Losses

OrthoPediatrics Corp. (Nasdaq Global Market: KIDS) disclosed net revenue of $70,508 thousand for the three months ended June 30, 2026, representing an increase from $61,082 thousand in the comparable prior-year quarter. For the six months ended June 30, 2026, the company reported net revenue of $129,869 thousand, up from $113,493 thousand for the six months ended June 30, 2025, according to the filing.

The company reported cost of revenue of $18,142 thousand for Q2 2026, yielding a gross profit of $52,366 thousand. Total operating expenses for the quarter were $56,434 thousand, which included sales and marketing expenses of $21,294 thousand, general and administrative expenses of $32,814 thousand, research and development costs of $2,325 thousand, and restructuring charges of $1 thousand, the filing disclosed. The resulting operating loss for Q2 2026 was $4,068 thousand, compared to an operating loss of $10,657 thousand in Q2 2025.

On the balance sheet as of June 30, 2026, the filing reported total current assets of $252,508 thousand, including cash of $17,001 thousand, short-term investments of $28,878 thousand, and inventories of $137,567 thousand. Total liabilities stood at $167,774 thousand, with long-term obligations including a long-term term loan of $48,436 thousand and a long-term convertible note of $48,803 thousand. Total stockholders' equity was $343,614 thousand as of June 30, 2026, compared to $346,596 thousand at December 31, 2025. Goodwill increased to $118,461 thousand from $109,269 thousand at year-end 2025. The filing notes that it contains forward-looking statements subject to the company's cautionary language regarding known and unknown risks and uncertainties.

What Was Disclosed

OrthoPediatrics Corp. filed a Form 10-Q for the quarter ended June 30, 2026, disclosing Q2 net revenue of $70,508 thousand, an operating loss of $4,068 thousand, a net loss of $7,163 thousand, total assets of $511,388 thousand, and an accumulated deficit of $293,062 thousand.